Domingo, 16 Junio, 2019

Lannett Co Inc (NYSE:LCI) Valuation According To Analysts

Manuel Armenta | 09 May, 2017, 10:37

Other equities research analysts also recently issued research reports about the company. Oppenheimer Holdings Inc. reiterated a "hold" rating on shares of Lannett Company in a research report on Saturday, March 25th. (NYSE:LCI) bumped up the target price from $0.00 to $29.00 that suggested an upside of 0.36%. State Street Corp now owns 1,186,674 shares of the company's stock valued at $26,169,000 after buying an additional 142,616 shares during the last quarter. The stock's market cap is $811.27 million. Lannett Company, Inc. has recorded a 50-day average of $23.52 and a two hundred day average of $22.32. Over the 52-week time span, the stock notched a high price of $39.99 and its minimum price was $16.75.

Insider Trades for Lannett Company, Inc. show that the latest trade was made on 23 April 2017 where Bedrosian (Arthur P), the Chief Executive Officer completed a transaction type "Sell" in which 663 shares were traded at a price of $24.3. Lannett Company had a negative net margin of 3.48% and a positive return on equity of 21.95%. The business had revenue of $165.72 million for the quarter, compared to the consensus estimate of $170.28 million. Earnings, with 7 analysts believing the company would generate an Average Estimate of $0.8. "(LCI)" was reported by BBNS and is the sole property of of BBNS. If you are reading this article on another website, it was stolen and republished in violation of USA and global copyright & trademark law. (NYSE:LCI) to Hold in a statement released on 5/04/2017.

In other news, CEO Arthur P. Bedrosian acquired 10,000 shares of Lannett Company stock in a transaction on Monday, February 6th.

Institutional investors now hold around $773 million or 92.4% in LCI stock. Acrospire Investment Management LLC now owns 7,356 shares of the company's stock valued at $195,000 after buying an additional 700 shares in the last quarter. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 15.04% of the company's stock.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Five research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Deerfield Management Co. purchased a new position in Lannett Company during the fourth quarter valued at approximately $44,266,000.

In recent action, Lannett Company, Inc. JPMorgan Chase & Co. now owns 36,700 shares of the company's stock worth $975,000 after buying an additional 36,435 shares in the last quarter. Acadian Asset Management LLC increased its stake in Lannett Company by 5,853.3% in the third quarter. Snow Capital Management LP now owns 1,638,072 shares of the company's stock worth $43,524,000 after buying an additional 1,007,907 shares during the period. Institutional investors own 80.82% of the company's stock.

About Lannett Company Lannett Company, Inc develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc As of June 30, 2016, the Company's products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules.